Browsing Tag
Acute myeloid leukemia
36 posts
Hemogenyx Pharmaceuticals stock jumps after third patient in CAR-T AML trial shows safety and early efficacy
Hemogenyx Pharmaceuticals (LSE: HEMO) stock jumps 24% after third patient treated in CAR-T AML trial shows safety and early efficacy.
September 17, 2025
Moleculin Biotech (NASDAQ: MBRX) launches stock offering to support pivotal cancer drug trial and IND filings
Moleculin Biotech to raise $5.9M to fund its Phase 3 trial for Annamycin and expand oncology pipeline. Explore what this means for AML treatment and investors.
June 20, 2025
Senti Biosciences gets FDA orphan drug status for SENTI-202 in relapsed AML treatment
Senti Biosciences earns FDA orphan drug designation for SENTI-202 in AML. Find out how this logic-gated CAR-NK therapy could reshape leukemia treatment.
June 18, 2025
CERo Therapeutics gets FDA boost for CER-1236, eyes breakthrough in AML cell therapy
CERo Therapeutics secures FDA orphan drug status for CER-1236 in AML, advancing its novel CER-T immunotherapy platform. Read what this means for investors.
June 17, 2025
Moleculin Biotech moves forward with pivotal Annamycin trial in AML after FDA backing
Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing innovative treatments for acute myeloid leukemia,…
February 13, 2025
Hemogenyx Pharmaceuticals launches Phase I AML trial for HG-CT-1 CAR-T therapy
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a leading biopharmaceutical company, has taken a significant step forward in the fight…
January 5, 2025
Aptevo Therapeutics achieves major breakthrough with mipletamig in acute myeloid leukemia
Aptevo Therapeutics has unveiled remarkable findings from Cohort 1 of its RAINIER clinical trial for mipletamig, a bispecific…
December 12, 2024
OncoVerity accelerates AML treatment with Series A extension
OncoVerity, a leader in integrating bioinformatics with oncology drug development, has closed a Series A extension financing round,…
November 23, 2024
Why Kura Oncology shares tumbled after securing a $1.2bn cancer-drug partnership
Kura Oncology, Inc., a clinical-stage biopharmaceutical innovator, and Japan-based pharmaceutical leader Kyowa Kirin Co., Ltd., have entered into…
November 21, 2024
Thermo Fisher Scientific and NCI launch myeloMATCH trial to advance AML and MDS treatment
In a significant advancement in cancer treatment, Thermo Fisher Scientific Inc. (NYSE: TMO) has partnered with the National…
July 13, 2024